<DOC>
	<DOCNO>NCT00704288</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate 6-month progression-free survival rate XL184 subject recurrent progressive glioblastoma multiforme . XL184 new chemical entity inhibit VEGFR2 , MET RET , kinases implicated tumor formation , growth migration .</brief_summary>
	<brief_title>Study XL184 ( Cabozantinib ) Adults With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>The subject locally determine histologically confirm diagnosis Grade 4 astrocytic tumor . The subject receive prior standard radiation Grade 3 4 astrocytic tumor . The subject receive prior temozolomide therapy Grade 3 4 astrocytic tumor ( first relapse , subject must receive temozolomide progression , intolerance , completion plan therapy ; second relapse , subject must receive temozolomide progression , intolerance , completion plan therapy either firstline treatment treatment first relapse ) . The subject first second Grade 4 relapse , define one two progression Grade 4 astrocytic tumor since original diagnosis grade glioma . The subject must baseline brain MRI scan within 14 day prior first dose XL184 either receive glucocorticoid 5 day prior baseline MRI scan stable dose glucocorticoid 5 day prior baseline MRI scan . Subjects undergone recent resection biopsy tumor eligible long follow condition apply : First dose XL184 occurs least 28 day surgery , subject recover effect surgery , subject measurable residual disease . The subject least 18 year old . The subject KPS ( Karnofsky Performance Scale ) ≥ 70 % . The subject capable understanding protocol sign informed consent document . The subject adequate organ marrow function . Sexually active subject ( male female ) must agree use medically accept method contraception course study 3 month follow discontinuation study drug . Female subject childbearing potential must negative pregnancy test enrollment . The subject receive nonstandard radiation therapy glioblastoma , nonantiangiogenic therapy ( include investigational agent , smallmolecule kinase inhibitor , biologic agent ) noncytotoxic hormonal agent within 28 day first schedule dose XL184 mitomycin C within 42 day first schedule dose XL184 , investigational therapy ( include agent specify ) within 28 day first schedule dose XL184 , prior treatment nitrosoureas ( include carmustine wafer ) time . Some subject may prior VEGF VEGFR2based antiangiogenic therapy ( bevacizumab , cediranib , pazopanib ) . Some subject may bevacizumab within 14 day first schedule dose XL184 . The subject receive warfarin ( coumarin derivative ) study entry unable switch low molecular weight heparin . The subject evidence acute intracranial intratumoral hemorrhage either MRI computerize tomography ( CT ) scan . Subjects resolve hemorrhage change , punctate hemorrhage , hemosiderin may enter study . The subject unable undergo MRI scan ( eg , pacemaker ) . The subject receive enzymeinducing antiepileptic agent within 2 week first dose XL184 ( eg , carbamazepine , phenytoin , phenobarbital , primidone ) . The subject recover National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 Grade ≤ 1 adverse event ( AEs ) due surgery , antineoplastic agent , investigational drug , medication administer study enrollment . The subject evidence wound dehiscence . The subject pregnant breastfeeding . The subject serious intercurrent illness , uncontrolled hypertension , unhealed wound recent surgery cardiac arrhythmias recent history significant disease either symptomatic congestive heart failure unstable angina pectoris within past 3 month , myocardial infarction within past 6 month , active infection require systemic treatment/hospitalization within 2 week first schedule dose XL184 The subject inherit bleed diathesis coagulopathy risk bleeding . The subject receive live virus vaccine within 28 day inactivate vaccine within 7 day prior first dose XL184 . The subject another diagnosis malignancy ( unless nonmelanoma skin cancer , situ carcinoma cervix , malignancy diagnose ≥ 2 year previously ) currently evidence malignancy ( unless nonmelanoma skin cancer situ carcinoma cervix ) . The subject know allergy hypersensitivity component XL184 formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>GBM</keyword>
	<keyword>Malignant glioma</keyword>
</DOC>